Commentary| Volume 37, 101412, January 2020

Clinical observation during alemtuzumab administration

Published:September 25, 2019DOI:


      • Alemtuzumab has been associated with stroke and cervicocephalic dissections.
      • Monitoring blood pressure is currently recommended by the EMA.
      • Monitoring blood pressure is not useful in predicting these rare side effects.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Durand-Dubief F.
        • Marignier R.
        • Berthezene Y.
        • Cottin J.
        • Nighoghossian N.
        • Vukusic S
        Spontaneous multiple cervical artery dissections after alemtuzumab.
        Mult. Scler. J. 2019;
        • Azevedo C.J.
        • Kutz C.
        • Dix A.
        • Boster A.
        • Sanossian N.
        • Kaplan J
        Intracerebral hemorrhage during alemtuzumab administration.
        Lancet Neurol. 2019; 18: 329-331
      1. US FDA. FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug Lemtrada (alemtuzumab) [Accessed 13 May; 2019]. Available from:

      2. EMA. Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing [Accessed 13 May 2019]. Available from:

        • Chinea A.
        • Honeycutt W.D.
        • Miller T.
        • Graves D.
        • Jacobs A.
        • Wu J.
        • et al.
        Clinically insignificant effect of alemtuzumab infusions on vital signs: a prospective observational study in patients with relapsing-remitting multiple sclerosis.
        Int. J. MS Care. 2019;